Garden Grove, CANCT07491458Now EnrollingIRB Ready

MASH - Metabolic Dysfunction-Associated Steatohepatitis Clinical Trial in Garden Grove, CA

Access cutting-edge mash - metabolic dysfunction-associated steatohepatitis treatment through this clinical trial at a research site in Garden Grove. Study-provided care at no cost to qualified participants.

Sponsored by Rivus Pharmaceuticals, Inc.

Quick Self-Assessment

See if you qualify for this Garden Grove location

Preparing your pre-screening questions…

Expert Care in Garden Grove

Access mash - metabolic dysfunction-associated steatohepatitis specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related mash - metabolic dysfunction-associated steatohepatitis treatment provided free

Apply for This Garden Grove Location

Check if you qualify for this mash - metabolic dysfunction-associated steatohepatitis clinical trial in Garden Grove, CA

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Garden Grove

    Convenient for CA residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Garden Grove site if eligible
  4. 4Begin participation

About This MASH - Metabolic Dysfunction-Associated Steatohepatitis Study in Garden Grove

Rivus Pharmaceuticals. Inc. is sponsoring this research study to assess the safety and tolerability of HU6 as a possible treatment for patients diagnosed with metabolic dysfunction-associated steatohepatitis (MASH). The study will also assess safety, pharmacokinetics (PK) and changes in liver fat content related to patients diagnosed with MASH.

Sponsor: Rivus Pharmaceuticals, Inc.

Who Can Participate

Inclusion Criteria

Male and female ≥30 years of age at time of signing the informed consent.
Diagnosed with metabolic dysfunction-associated steatohepatitis (MASH)
Women of childbearing potential must not be pregnant or breastfeeding and must use and agree to continue to use a highly effective contraceptive method throughout time on study.
Body Mass Index (BMI) ≥27.0 kg/m2 to ≤44 kg/m2

Exclusion Criteria

Have acute or chronic hepatitis, signs, and symptoms of any other liver disease (eg, Wilson's disease) other than MASH
Cholecystectomy or any other surgical or medical condition or history that may potentially alter the absorption, metabolism, or excretion of study treatment.
History (including any family history) of malignant hyperthermia.
History of malignancy within 5 years (except cutaneous basal or squamous cell carcinoma, carcinoma-in-situ, or low-grade prostate cancer).
History of the following cardiovascular conditions within 3 months prior to randomization: acute myocardial infarction, cerebrovascular accident (stroke), unstable angina, hospitalization due to congestive heart failure (CHF), or acute CHF.
Significant and unstable lung disease (chronic obstructive pulmonary disease \[COPD\], emphysema, pulmonary fibrosis, or asthma) requiring oxygen or chronic daily medication. Note that mild, stable COPD and asthma on inhalers are allowed.
Monogenetic diabetes or type 1 diabetes.
History of ketoacidosis or hyperosmolar state requiring hospitalization in the 6 months prior to Screening.
History of agranulocytosis.
History of or active evidence of ophthalmological conditions
Untreated, uncontrolled, or unstable hypertension
Use of any of the following medications/therapies: Vitamin E: use of ursodiol or high-dose vitamin E (\>400 IU/day) for a duration of \>1 month within 6 months or started high dose vitamin E for any duration within 3 months prior to screening
Within 3 months prior to screening or plan to use prior to coming off study drug: resmetirom (Rezdiffra®), GLP 1 agonists and gastric inhibitory polypeptide (GIP)/GLP-1 agonists, Weight loss medications/therapies including: herbal preparation, over the counter (OTC) drug, mail order or prescription drug, Oral antidiabetic medications/therapies including: insulin, meglitinides, thiazolidinediones. Prescription or OTC stimulants. Recent or current use of obeticholic acid (Ocaliva®), systemic corticosteroids, methotrexate, tamoxifen, amiodarone, or long-term use of tetracyclines. Warfarin, heparin, factor Xa inhibitors due to risk of bleeding, Medications with high risk of idiosyncratic drug-induced neutropenia (IDIN) or agranulocytosis.
History of hepatitis or human immunodeficiency virus (HIV1 \& HIV2)
Intolerance to MRI or with conditions contraindicated for MRI procedures
Participation in another clinical trial at the time of screening or exposure to any investigational product, including topical agents, within 28 days prior to starting study treatment
Additional inclusion/exclusion criteria could apply

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Garden Grove?

Yes, this clinical trial (NCT07491458) has an active research site in Garden Grove, CA that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

MASH - Metabolic Dysfunction-Associated Steatohepatitis Treatment Options in Garden Grove, CA

If you're searching for mash - metabolic dysfunction-associated steatohepatitis treatment options in Garden Grove, CA, this clinical trial (NCT07491458) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Garden Grove research site is actively enrolling participants for this clinical trial. You'll receive care from experienced mash - metabolic dysfunction-associated steatohepatitis specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all mash - metabolic dysfunction-associated steatohepatitis clinical trials near you to find additional studies recruiting in your area.

More Essential Tremor Trials in Garden Grove, CA

See all essential tremor clinical trials recruiting in Garden Grove — not just this study.

Browse Essential Tremor Trials in Garden Grove →

Browse More Trials by Condition

Essential Tremor TrialsAnkylosing Spondylitis TrialsNASH TrialsErectile Dysfunction TrialsInterstitial Cystitis TrialsMyalgic Encephalomyelitis TrialsAll Conditions →

Ready to Join in Garden Grove?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Garden Grove, CA